Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Lead Product(s) : Chondroitin Sulfate Sodium
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioiberica Rebrands Its Range of Nutraceutical Ingredients for Healthcare
Details : Bioiberica’s native (undenatured) type II collagen, Collavant® n2 (previously b2-Cool®) and the addition of Tendaxion® - a new brand for its tendon health ingredient.
Product Name : CSbioactive
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 05, 2021
Lead Product(s) : Chondroitin Sulfate Sodium
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chondroitin Sulfate Sodium,Glucosamine Hydrochloride
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Primary Care Study With Chondroitin Sulfate and Glucosamine Hydrochloride in Hand Osteoarhritis
Details : Droglican is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Osteoarthritis, Hand.
Product Name : Droglican
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
July 06, 2016
Lead Product(s) : Chondroitin Sulfate Sodium,Glucosamine Hydrochloride
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chondroitin Sulfate Sodium,Glucosamine Hydrochloride
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : Artialis
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Droglican is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Osteoarthritis, Knee.
Product Name : Droglican
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
July 01, 2016
Lead Product(s) : Chondroitin Sulfate Sodium,Glucosamine Hydrochloride
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : Artialis
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chondroitin Sulfate Sodium,Glucosamine
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Chondroitin is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Osteoarthritis, Knee.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 30, 2011
Lead Product(s) : Chondroitin Sulfate Sodium,Glucosamine
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chondroitin Sulfate Sodium
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Chondroitin Sulfate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Osteoarthritis, Knee.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 16, 2011
Lead Product(s) : Chondroitin Sulfate Sodium
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chondroitin Sulfate Sodium
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Chondroitin Sulfate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Osteoarthritis, Knee.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 22, 2010
Lead Product(s) : Chondroitin Sulfate Sodium
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable